Peroxisome proliferator-activated receptor alpha plays a crucial role in behavioral repetition and cognitive flexibility in mice

Molecular Metabolism

Volumn 4, Issue 7, 2015, Pages 528-536

  D'Agostino, Giuseppe ^a,b   Cristiano, Claudia ^a,b,c   Lyons, David J ^b   Citraro, Rita ^d   Russo, Emilio ^d   Avagliano, Carmen ^a   Russo, Roberto ^a   Raso, Giuseppina Mattace ^a   Meli, Rosaria ^a   De Sarro, Giovambattista ^d   Heisler, Lora K ^b   Calignano, Antonio ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b ROWETT RESEARCH INSTITUTE   (United Kingdom)

^c ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

^d UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Ketamine; Lipids; Memory; Neurodevelopmental disorders; Nuclear receptor; Stereotyped behavior

Indexed keywords

2 [4 [2 [3 CYCLOHEXYL 1 (4 CYCLOHEXYLBUTYL)UREIDO]ETHYL]PHENYLTHIO] 2 METHYLPROPIONIC ACID; DIZOCILPINE; KETAMINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; RISPERIDONE;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTISM; BODY WEIGHT; BRAIN FUNCTION; COGNITION; COMPULSION; CONTROLLED STUDY; DNA MODIFICATION; DRUG ACTIVITY; ELECTROENCEPHALOGRAPHY; ENERGY METABOLISM; GENE DISRUPTION; GENE LOSS; GENETIC ASSOCIATION; GROOMING; HETEROZYGOSITY; HIPPOCAMPUS; LEARNING AND MEMORY TEST; LOCOMOTION; MALE; MARBLES BURYING TEST; MOUSE; NONHUMAN; NOVEL OBJECT RECOGNITION TEST; OPEN FIELD TEST; PPAR ALPHA GENE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PSYCHOSIS; SCHIZOPHRENIA; SPATIAL LEARNING; SPATIAL MEMORY;

MUS;

EID: 84931572987     PISSN: None     EISSN: 22128778     Source Type: Journal    
DOI: 10.1016/j.molmet.2015.04.005     Document Type: Article

References (38)

1. Vincenzi B., Borba C.P., Gray D.A., Copeland P.M., Wang X., Fan X., et al. An exploratory study examining lipid-lowering medications in reducing fasting serum lipids in schizophrenia patients treated with atypical antipsychotics. Annals of Clinical Psychiatry 2013, 25:141-148.
2. Staels B., Fruchart J.C. Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 2005, 54:2460-2470.
3. Forman B.M., Chen J., Evans R.M. The peroxisome proliferator-activated receptors: ligands and activators. Annals of the New York Academy of Sciences 1996, 804:266-275.
4. Kliewer S.A., Forman B.M., Blumberg B., Ong E.S., Borgmeyer U., Mangelsdorf D.J., et al. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proceedings of the National Academy of Sciences USA 1994, 91:7355-7359.
5. Arakawa R., Tamehiro N., Nishimaki-Mogami T., Ueda K., Yokoyama S. Fenofibric acid, an active form of fenofibrate, increases apolipoprotein A-I-mediated high-density lipoprotein biogenesis by enhancing transcription of ATP-binding cassette transporter A1 gene in a liver X receptor-dependent manner. Arteriosclerosis, Thrombosis, and Vascular Biology 2005, 25:1193-1197.
6. Nakaya K., Tohyama J., Naik S.U., Tanigawa H., MacPhee C., Billheimer J.T., et al. Peroxisome proliferator-activated receptor-alpha activation promotes macrophage reverse cholesterol transport through a liver X receptor-dependent pathway. Arteriosclerosis, Thrombosis, and Vascular Biology 2011, 31:1276-1282.
7. Grover S., Kumar P., Singh K., Vikram V., Budhiraja R.D. Possible beneficial effect of peroxisome proliferator-activated receptor (PPAR)-alpha and gamma agonist against a rat model of oral dyskinesia. Pharmacology Biochemistry and Behavior 2013, 111:17-23.
8. Melis M., Carta S., Fattore L., Tolu S., Yasar S., Goldberg S.R., et al. Peroxisome proliferator-activated receptors-alpha modulate dopamine cell activity through nicotinic receptors. Biological Psychiatry 2010, 68:256-264.
9. Ananth J., Venkatesh R., Burgoyne K., Gadasalli R., Binford R., Gunatilake S. Atypical antipsychotic induced weight gain: pathophysiology and management. Annals of Clinical Psychiatry 2004, 16:75-85.
10. Kim E.K., Neggers Y.H., Shin C.S., Kim E., Kim E.M. Alterations in lipid profile of autistic boys: a case control study. Nutrition Research 2010, 30(4):255-260.
11. Allen N.C., Bagade S., McQueen M.B., Ioannidis J.P., Kavvoura F.K., Khoury M.J., et al. Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nature Genetics 2008, 40:827-834.
12. Hoeffer C.A., Tang W., Wong H., Santillan A., Patterson R.J., Martinez L.A., et al. Removal of FKBP12 enhances mTOR-Raptor interactions, LTP, memory, and perseverative/repetitive behavior. Neuron 2008, 60:832-845.
13. Karayannis T., Au E., Patel J.C., Kruglikov I., Markx S., Delorme R., et al. Cntnap4 differentially contributes to GABAergic and dopaminergic synaptic transmission. Nature 2014, 511:236-240.
14. Shmelkov S.V., Hormigo A., Jing D., Proenca C.C., Bath K.G., Milde T., et al. Slitrk5 deficiency impairs corticostriatal circuitry and leads to obsessive-compulsive-like behaviors in mice. Nature Medicine 2010, 16:598-602.
15. Welch J.M., Lu J., Rodriguiz R.M., Trotta N.C., Peca J., Ding J.D., et al. Cortico- striatal synaptic defects and OCD-like behaviours in Sapap3-mutant mice. Nature 2007, 448:894-900.
16. Behrens M.M., Ali S.S., Dao D.N., Lucero J., Shekhtman G., Quick K.L., et al. Ketamine-induced loss of phenotype of fast-spiking interneurons is mediated by NADPH-oxidase. Science 2007, 318:1645-1647.
17. Wilson F.A., O'Scalaidhe S.P., Goldman-Rakic P.S. Functional synergism between putative gamma-aminobutyrate-containing neurons and pyramidal neurons in prefrontal cortex. Proceedings of the National Academy of Sciences USA 1994, 91:4009-4013.
18. Markram H., Toledo-Rodriguez M., Wang Y., Gupta A., Silberberg G., Wu C. Interneurons of the neocortical inhibitory system. Nature Reviews Neuroscience 2004, 5:793-807.
19. Breier A., Malhotra A.K., Pinals D.A., Weisenfeld N.I., Pickar D. Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. American Journal of Psychiatry 1997, 154:805-811.
20. Jackson M.E., Homayoun H., Moghaddam B. NMDA receptor hypofunction produces concomitant firing rate potentiation and burst activity reduction in the prefrontal cortex. Proceedings of the National Academy of Sciences USA 2004, 101:8467-8472.
21. Carlen M., Meletis K., Siegle J.H., Cardin J.A., Futai K., Vierling-Claassen D., et al. A critical role for NMDA receptors in parvalbumin interneurons for gamma rhythm induction and behavior. Molecular Psychiatry 2012, 17:537-548.
22. Cardin J.A., Carlen M., Meletis K., Knoblich U., Zhang F., Deisseroth K., et al. Driving fast-spiking cells induces gamma rhythm and controls sensory responses. Nature 2009, 459:663-667.
23. Hakami T., Jones N.C., Tolmacheva E.A., Gaudias J., Chaumont J., Salzberg M., et al. NMDA receptor hypofunction leads to generalized and persistent aberrant gamma oscillations independent of hyperlocomotion and the state of consciousness. PloS One 2009, 4:e6755.
24. McFarlane H.G., Kusek G.K., Yang M., Phoenix J.L., Bolivar V.J., Crawley J.N. Autism-like behavioral phenotypes in BTBR T+tf/J mice. Genes Brain Behavior 2008, 7:152-163.
25. Chadman K.K., Guariglia S.R., Yoo J.H. New directions in the treatment of autism spectrum disorders from animal model research. Expert Opinion on Drug Discovery 2012, 7:407-416.
26. Pearson B.L., Defensor E.B., Pobbe R.L., Yamamoto L.H., Bolivar V.J., Blanchard D.C., et al. Mecp2 truncation in male mice promotes affiliative social behavior. Behavior Genetics 2012, 42:299-312.
27. Nakazawa K., Zsiros V., Jiang Z., Nakao K., Kolata S., Zhang S., et al. GABAergic interneuron origin of schizophrenia pathophysiology. Neuropharmacology 2012, 62:1574-1583.
28. Lewis D.A., Curley A.A., Glausier J.R., Volk D.W. Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia. Trends in Neuroscience 2012, 35:57-67.
29. Reynolds G.P., Zhang Z.J., Beasley C.L. Neurochemical correlates of cortical GABAergic deficits in schizophrenia: selective losses of calcium binding protein immunoreactivity. Brain Research Bulletin 2001, 55:579-584.
30. Lisman J.E., Coyle J.T., Green R.W., Javitt D.C., Benes F.M., Heckers S., et al. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends in Neuroscience 2008, 31:234-242.
31. McDougle C.J., Scahill L., McCracken J.T., Aman M.G., Tierney E., Arnold L.E., et al. Research Units on Pediatric Psychopharmacology (RUPP) autism network. Background and rationale for an initial controlled study of risperidone. Child and Adolescent Psychiatric Clinics of North America 2000, 9:201-224.
32. McDougle C.J., Stigler K.A., Erickson C.A., Posey D.J. Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders. The Journal of Clinical Psychiatry 2008, 69(Suppl. 4):15-20.
33. Huang T.L., Chen J.F. Serum lipid profiles and schizophrenia: effects of conventional or atypical antipsychotic drugs in Taiwan. Schizophrenia Research 2005, 80:55-59.
34. Henderson D.C., Cagliero E., Gray C., Nasrallah R.A., Hayden D.L., Schoenfeld D.A., et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. American Journal of Psychiatry 2000, 157:975-981.
35. Koro C.E., Fedder D.O., L'Italien G.J., Weiss S., Magder L.S., Kreyenbuhl J., et al. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Archives of General Psychiatry 2002, 59:1021-1026.
36. Atmaca M., Kuloglu M., Tezcan E., Gecici O., Ustundag B. Weight gain, serum leptin and triglyceride levels in patients with schizophrenia on antipsychotic treatment with quetiapine, olanzapine and haloperidol. Schizophrenia Research 2003, 60:99-100.
37. Melkersson K.I., Dahl M.L. Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics clozapine and olanzapine in patients on treatment with therapeutic doses. Psychopharmacology (Berl) 2003, 170:157-166.
38. Knauf C., Rieusset J., Foretz M., Cani P.D., Uldry M., Hosokawa M., et al. Peroxisome proliferator-activated receptor-alpha-null mice have increased white adipose tissue glucose utilization, GLUT4, and fat mass: role in liver and brain. Endocrinology 2006, 147:4067-4078.